Identifying genetic predictors of durable clinical benefit to pembrolizumab in advanced non-small cell lung cancer alone and in combination with chemotherapy.

Protocol: 
AAAQ5450
Phase: 
II

Identifying genetic predictors of durable clinical benefit to pembrolizumab in advanced non-small cell lung cancer alone and in combination with chemotherapy.

This is a research study to test the effectiveness of pembrolizumab on cancer types having a known relationship to smoking carcinogen exposure. The study will enroll 120 subjects age 18 and above with advanced solid tumor related to smoking exposure. All patients will receive the treatment of pembrolizumab. The study aims to determine if tumor genetics can predict the effect of pembrolizumab on non-small-cell lung carcinoma.

Are you Eligible? (Inclusion Criteria)

-Have measurable disease based on RECIST 1.1
-Be willing to undergo tumor biopsies pre-treatment and at C2D8 (+/- 3 days). For
stable disease or responders > 3 months, also repeat biopsy at progression
-No prior monoclonal antibody within 4 weeks prior to study Day 1
-No diagnosis of immunodeficiency or is not receiving systemic steroid therapy or
any other form of immunosuppressive therapy within 7 days prior to the first dose
of trial treatment.

Specialty Area(s)

Immunotherapy

Trial Location

Herbert Irving Comprehensive Cancer Center
161 Fort Washington Ave.
Herbert Irving Pavilion
New York, NY 10032
United States

ColumbiaDoctors Midtown
51 West 51st St.
New York, NY 10019
United States